{
  "abstract": "Background: Systemic treatment choices after failure of standard therapy are limited for malignant mesothelioma. Oral vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have been incorporated into salvage treatment strategies, but real-world evidence regarding their effectiveness and safety remains scarce. Methods: We retrospectively analyzed a single-center cohort comprising patients with pathologically confirmed malignant mesothelioma treated at Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center between 1 April 2017 and 16 March 2023. Patients with unresectable disease who received a VEGFR-TKI-containing regimen and had sufficient clinical follow-up for outcome assessment were included. Progression-free survival (PFS) served as the primary endpoint. Objective response rate (ORR), disease control rate (DCR), overall survival (OS) from VEGFR-TKI initiation, and recorded adverse events were included as secondary endpoints. Results: The cohort comprised 48 patients, with a median follow-up of 24.0 months. The Kaplan–Meier estimated median PFS was 4.8 months (95% CI, 2.9–8.8), and median OS from VEGFR-TKI initiation was 17.9 months (95% CI, 13.5–not estimable). Among 39 response-evaluable patients, 6 achieved partial response, 20 had stable disease, and 13 had progressive disease as their best overall response, yielding an ORR of 15.4% and a DCR of 66.7%. Two patients remained progression-free for more than 24 months. Grade 3 adverse events in the records included hematuria, hypertension, and nausea/vomiting; no grade 4 or grade 5 adverse event was documented. Conclusions: VEGFR-TKI-containing therapy was associated with clinically relevant disease control in unresectable malignant mesothelioma, with durable benefit observed in a small subset of patients. These observations warrant further evaluation of VEGFR-TKI-based salvage strategies in larger multicenter cohorts.",
  "abstract_shown": true,
  "affiliations": [
    "State Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Zheng Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Jia Zhong"
    },
    {
      "affs": [
        0
      ],
      "name": "Rui Wan"
    },
    {
      "affs": [
        0
      ],
      "name": "Jian-Chun Duan",
      "orcid": "0000-0003-3300-1707"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhi-Jie Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Hua Bai",
      "orcid": "0000-0002-3179-8137"
    },
    {
      "affs": [
        0
      ],
      "name": "Jie Wang",
      "orcid": "0000-0002-5602-0487"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fbaw6zm9y47fq.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18213541",
  "fulltext_url": null,
  "id": "fbaw6zm9y47fq",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://www.mdpi.com/2072-6694/18/21/3541",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-04",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/fbaw6zm9y47fq.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:21:40Z",
      "native_id": "10.3390/cancers18213541",
      "source": "crossref",
      "url": "https://www.mdpi.com/2072-6694/18/21/3541"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2072-6694",
      "subfield": "oncology"
    }
  ],
  "title": "Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study",
  "title_text": "Real-World Outcomes of Oral VEGFR Tyrosine Kinase Inhibitor-Containing Therapy in Unresectable Malignant Mesothelioma: A Single-Center Retrospective Study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T00:21:25Z",
  "url": "https://research.draconitic.com/paper/fbaw6zm9y47fq",
  "venue": "Cancers",
  "versions": []
}